AMGN vs EBS · P/E 24, rev $36.75B vs rev $1.04B
Amgen Inc (AMGN) versus Emergent Biosolutions Inc (EBS) — a side-by-side from cached financials, not a winner call.
Amgen Inc (AMGN) is a drug manufacturers - general company listed on US.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
Latest reported AMGN revenue for 2025-12-31 was $36.75B. Net income was $7.71B. Revenue was up 10.0% from 2024-12-31 to 2025-12-31. AMGN currently screens at market cap $188.67B and trailing P/E 24.3.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
AMGN currently screens at market cap $188.67B and trailing P/E 24.3. EBS currently screens at market cap $416.4M.
Not investment advice. Open the AMGN and EBS stock pages for the full models.
Not investment advice.